Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilbert J Burckart

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
Pharmaceutical Research|March 27, 2025
PBPK Modeling to Support Bioavailability and Bioequivalence Assessment in Pediatric PopulationsFang Wu, Eleftheria Tsakalozou, Gilbert J Burckart, et al.
Pharmacotherapy|June 26, 2008
Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosisPaul M Beringer, Jane Kriengkauykiat, Xiyun Zhang, et al.
Pharmacotherapy|July 29, 2008
Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug useFelix W Frueh, Shashi Amur, Padmaja Mummaneni, et al.
Journal of Clinical Pharmacology|March 11, 2025
Dose Ranging in Pediatric Drug Development Trials Submitted to the US FDA 2012-2020Carlton K K Lee, Eugenia Kwon, Francis G Green, et al.
The AAPS Journal|June 29, 2023
Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case StudyGopal Pawar, Fang Wu, Liang Zhao, et al.
Clinical Pharmacology and Therapeutics|December 9, 2017
Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug AdministrationDionna J Green, Xiaomei I Liu, Tianyi Hua, et al.
Clinical Pharmacology and Therapeutics|July 23, 2020
Creatinine-Based Renal Function Assessment in Pediatric Drug Development: An Analysis Using Clinical Data for Renally Eliminated DrugsYifei Zhang, Catherine M Sherwin, Daniel Gonzalez, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 18, 2024
Landscape of regulatory quantitative systems pharmacology submissions to the U.S. Food and Drug Administration: An update reportJane P F Bai, Guansheng Liu, Miao Zhao, et al.
Journal of Clinical Pharmacology|June 29, 2021
Applying the Noninferiority Paradigm to Assess Exposure-Response Similarity and Dose Between Pediatric and Adult PatientsQunshu Zhang, James Travis, Rebecca Rothwell, et al.
Journal of Clinical Pharmacology|June 13, 2014
Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study designJeremiah D Momper, Alyson Karesh, Dionna J Green, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
Pharmaceutical Research|March 27, 2025
PBPK Modeling to Support Bioavailability and Bioequivalence Assessment in Pediatric PopulationsFang Wu, Eleftheria Tsakalozou, Gilbert J Burckart, et al.
Pharmacotherapy|June 26, 2008
Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosisPaul M Beringer, Jane Kriengkauykiat, Xiyun Zhang, et al.
Pharmacotherapy|July 29, 2008
Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug useFelix W Frueh, Shashi Amur, Padmaja Mummaneni, et al.
Journal of Clinical Pharmacology|March 11, 2025
Dose Ranging in Pediatric Drug Development Trials Submitted to the US FDA 2012-2020Carlton K K Lee, Eugenia Kwon, Francis G Green, et al.
The AAPS Journal|June 29, 2023
Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case StudyGopal Pawar, Fang Wu, Liang Zhao, et al.
Clinical Pharmacology and Therapeutics|December 9, 2017
Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug AdministrationDionna J Green, Xiaomei I Liu, Tianyi Hua, et al.
Clinical Pharmacology and Therapeutics|July 23, 2020
Creatinine-Based Renal Function Assessment in Pediatric Drug Development: An Analysis Using Clinical Data for Renally Eliminated DrugsYifei Zhang, Catherine M Sherwin, Daniel Gonzalez, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 18, 2024
Landscape of regulatory quantitative systems pharmacology submissions to the U.S. Food and Drug Administration: An update reportJane P F Bai, Guansheng Liu, Miao Zhao, et al.
Journal of Clinical Pharmacology|June 29, 2021
Applying the Noninferiority Paradigm to Assess Exposure-Response Similarity and Dose Between Pediatric and Adult PatientsQunshu Zhang, James Travis, Rebecca Rothwell, et al.
Journal of Clinical Pharmacology|June 13, 2014
Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study designJeremiah D Momper, Alyson Karesh, Dionna J Green, et al.
Pageof 13